A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)

Exclusion Criteria

• •Arm MK-4716 + Pembrolizumab: Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study intervention
• •Arm MK-4716 + Pembrolizumab: Has received any prior immunotherapy and was discontinued from that treatment
• •Arm MK-4716 + Pembrolizumab: Has active autoimmune disease that has required systemic treatment in the past 2 years. Hormonal supplementation (eg, thyroxine, insulin, or physiologic corticosteroid) is allowed
• •History of human immunodeficiency virus infection
• •Has a known additional malignancy that is progressing or has required active treatment within the past 2 years
• •Has a known active central nervous system metastases and/or carcinomatous meningitis
• •History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease
• •Has active infection requiring systemic therapy
• •Has Hepatitis B or Hepatitis C virus infection
• •History of stem cell/solid organ transplant
• •Has not adequately recovered from major surgery or has ongoing surgical complications